KSTATION

Every other authenticity guide we have written starts from a product and asks how to confirm it is genuine. This one has to start a step earlier, because "mesotherapy product" does not name a kind of product at all. It names a way of delivering one. The consequence is practical rather than academic: two vials sitting side by side in the same order, both sold to you as mesotherapy, can belong to entirely different regulatory worlds, and the checks that authenticate one of them do nothing for the other. That is the whole difficulty, and it is why buyers who have learned to verify a toxin or a filler competently still get stuck here. The habits do not transfer, because the category is not a category. Mesotherapy names a technique, not a product class Mesotherapy describes a delivery method: a series of small, shallow injections placed across an area rather than a single deep placement. What goes into those injections is not specified by the word. In practice the term covers hydrating solutions, vitamin and antioxidant preparations, preparations sold for scalp use, products built around regenerative actives, and, when clinicians use the technique that way, dilute preparations of products that are otherwise injected conventionally. Our own catalogue makes the point without any argument being necessary. The products grouped under mesotherapy carry internal product types spanning skin boosters and ampoules, dermal fillers, contouring and lipolysis preparations, botulinum toxins, and regenerative products such as exosome preparations. That grouping is not sloppy. It reflects how the technique is actually used, and any honest grouping would look similar. But it means the question "how do I verify a mesotherapy product" has no single answer, in the same way that "how do I verify a thing sold in a box" has no single answer. So the first move in verification is not verification. It is classification. Before you can check whether a product is genuine, you have to establish what kind of thing the authorities consider it to be, because that determines which register holds its record, which fields that register keeps, and therefore what a genuine record even looks like. Three registers, one syringe In Korea the products used for mesotherapy sort into three buckets, and the bucket decides your entire verification procedure. We swept the Ministry of Food and Drug Safety open data registers on 10 August 2026 to check what each bucket actually returns.1 Where a mesotherapy product actually sits Drug register Device register Returns nothing by that name Typical examples Botulinum toxin, glutathione, vitamin preparations, thioctic acid HA fillers and tissue repair biomaterials Exosome preparations and various cosmetic ampoules What you can look up Active ingredient, supply classification, class code, licence holder, grant date Licence number and route, product category, holder, manufacturer field Nothing on the ingredient field of the drug register Supply classification Real and recorded Does not exist as a field Not applicable Verification leans on Register record plus physical and lot checks Licence record plus physical and lot checks Manufacturer documentation and channel accountability Three columns, three procedures. A buyer who applies the first column's habits to a third column product will conclude that something is wrong when nothing is, and a buyer who applies the third column's looseness to a first column product will skip the check that would have caught a problem. When it is a drug: what the register actually gives you For products that are licensed as drugs, the register is generous. Take botulinum toxin, which enters mesotherapy practice in dilute form. Querying the drug register on the active ingredient field for Clostridium Botulinum Toxin Type A returns 58 records, of which 57 are live. All 57 carry the same class code, toxins and toxoids, and all 57 carry the same supply classification: prescription only, without a single exception. The oldest live record dates to 13 July 1999.1 That uniformity is the useful part. When a field is filled the same way across every record in a category, any listing that contradicts it is telling you something. A toxin offered as though supply classification were a matter of vendor discretion is contradicting a field that 57 out of 57 records agree on. You do not need to know anything about the specific brand to know that the framing is wrong. The register also carries export wording inside product names, which is a frequent source of confusion in this category: 24 of those toxin records carry export naming. As we set out in our piece on what export wording on a Korean licence means, that wording is a category of Korean licensing, not a quality grade and not a statement about whether any other country has approved the product. Reading it as either is a mistake that cuts in both directions. The practical checks for this bucket are the ones we set out for botulinum toxins and for skin boosters: match the licence holder named on the carton against the register record, confirm the record is still live rather than withdrawn, and check that lot and expiry on the carton, the vial, and the paperwork all agree. When it is a device: a different set of fields Fillers used in mesotherapy technique, and the tissue repair biomaterials adjacent to them, are not in the drug register at all. Querying the device register on the tissue repair biomaterial product category returns 609 records, of which 458 are live.1 That is a substantial category, and its absence from the drug register is not evidence of anything, a point we made at length in why your HA filler is not in the Korean drug register. What matters for verification is that the device register keeps different fields. There is no supply classification on a device licence, so any listing that cites prescription status for a filler is citing a field that does not exist for that product. The licence number carries a route prefix that tells you domestic manufacture or import before you look anything up. The manufacturer field behaves differently from what buyers expect, being filled largely on imports, so its absence on a domestic licence is structural rather than suspicious. The physical verification layer, by contrast, is largely shared with the drug bucket, and our filler-specific work on distinguishing authentic Korean dermal fillers from counterfeits covers it in detail: serialisation on the carton, lot and expiry agreement across carton, unit and paperwork, and packaging and print quality against a known genuine reference. When the name returns nothing The third bucket is where most of the confusion in mesotherapy sits, and it needs to be handled carefully because it is easy to say something false here. Querying the drug register's active ingredient field for exosome returns zero records. We ran the query in three capitalisations, because the ingredient index is case sensitive and a single wrong capital silently returns nothing, and all three returned zero.1 So the finding is stable rather than an artefact of how we typed it. But here is the discipline that matters: "the register returns nothing for this name" and "this product is unregulated" are different statements, and only the first one is something we established. A product can return nothing on an ingredient query because it is licensed under a different name, because it sits in a register we did not query, or because it is regulated as a cosmetic rather than as a drug or device. We have been caught by the milder version of this before. When we worked through the tranexamic acid records, a product name search quietly deleted exactly the four records that broke the pattern, leaving a tidier and less accurate picture than the full ingredient sweep gave. A search returning less than the truth does not announce itself. So for third bucket products the honest position is this: the register is not going to authenticate them for you, and you should not read its silence as either a red flag or a clean bill of health. Verification shifts entirely onto the manufacturer documentation and the accountability of the channel, which is the weakest position of the three and worth knowing you are in. Checks that hold regardless of register Once you know which bucket you are in, a common layer applies to all three. These are the checks that do not depend on which authority holds the record. Lot and expiry agreement. The lot number and expiry on the outer carton, on the individual unit, and on the paperwork that came with the shipment should all be the same. Disagreement between any two of them is the single most informative failure, because it is difficult to produce by accident. Named holder, checked live. Whoever is named on the packaging should be findable in the appropriate register, and the record should be live rather than withdrawn. In the filler category roughly one record in four is withdrawn, so currency matters more than buyers assume. Packaging against a known reference. Print quality, colour, and finish compared against a unit you already trust. This is the check that catches the crude forgeries, and it only works if you have a genuine reference to compare with. Cold chain consistent with the product. A product whose format implies temperature control should arrive in a condition consistent with that, and the seller should be able to describe the handling rather than gesture at it. A seller who answers in specifics. Manufacturer, licence holder, licence number, lot, and the route the product travelled. An accountable channel answers these directly. A vague answer to a specific question is itself the finding. Red flags specific to mesotherapy Some failure patterns are peculiar to this category rather than general, and they follow from the same fact that makes verification hard: the word covers many things. Unlabelled or relabelled ampoules. Because mesotherapy preparations are often supplied in small ampoules and because clinicians sometimes prepare mixtures, the category has more tolerance than others for containers that arrive without full original labelling. That tolerance is exactly where counterfeits live. An ampoule you cannot trace to an original labelled unit is not verifiable, however plausible the rest of the transaction looks. A "cocktail" sold as a product. A mixture prepared by a seller is not a licensed product, whatever the components were before mixing. There is no register record for a combination that a vendor assembled, so there is nothing to verify against. This is a different situation from buying licensed components separately, and the distinction is worth insisting on. Classification claims that do not match the bucket. A filler described with prescription status, or a cosmetic ampoule described as though it carried a drug licence, is describing fields that do not exist for that product. As above, you do not need brand knowledge to spot this. You need to know which register the product belongs to, which is the first step of this guide. Numbers that are too clean. This is a general principle we have learned the hard way with the registers themselves, and it applies to vendor claims too. Results that land on suspiciously round figures, or a claim of complete coverage with no exceptions anywhere, are worth a second look rather than a first acceptance. Verifying a mesotherapy product, step by step Classify before you verify. Establish whether the product is licensed as a drug, as a device, or as neither under that name. Everything downstream depends on this and nothing upstream of it is reliable. Query the right register on the right field. Ingredient field for drugs, product category or licence number for devices. Mind capitalisation on the ingredient index, and prefer an ingredient sweep to a product name search where you have the choice. Match the named holder from the packaging to the register record, and confirm the record is live. Check lot and expiry agreement across carton, unit, and paperwork. Compare packaging against a reference unit you already trust. Ask the seller the specific questions and treat the shape of the answer as data. Confirm your own market's position separately. Korean licensing governs Korea. Whether a product may be imported or used where you are, and by whom, is decided by your own authority, and device rules and drug rules frequently differ within the same country. The limit of a register check A register confirms that a licence exists and what it says. It does not confirm that the object in your hand is the licensed product, which is what the physical and lot checks are for, and it does not say anything about whether importing or using that product is permitted where you are. Those are three separate questions with three separate answers, and passing one does not pass the others. If you want the surrounding context rather than the verification procedure, our explainer on what mesotherapy is and what it is not covers the technique itself, and mesotherapy versus skin boosters separates the technique from the product class it is most often confused with. The preparations this guide applies to sit within the mesotherapy range, alongside products such as Revs PRO 32, SELASTIN EXO PLUS and Atlantis Hair. Frequently asked questions Frequently asked How do I verify an authentic mesotherapy product? Start by classifying it rather than verifying it. Mesotherapy names a delivery technique, not a product class, so the products used for it sit in different registers: some are licensed as drugs, some as medical devices, and some return nothing on the drug register under their common name. Once you know which, the procedure follows: query the right register on the right field, match the named licence holder and confirm the record is live, then check lot and expiry agreement across carton, unit and paperwork. Are mesotherapy products regulated as drugs or as devices? Both, depending on the product. Botulinum toxin, glutathione and vitamin preparations sit in the drug register, where supply classification and class codes are recorded. Fillers and tissue repair biomaterials sit in the device register, which has no supply classification field at all. A third group, including exosome preparations, returns no records on the drug register's ingredient field under that name. The word mesotherapy does not tell you which of these you have. Why can I not find my mesotherapy product on the Korean register? There are several possible reasons and they are not equivalent. It may be a device rather than a drug, so it is in a different register. It may be licensed under an ingredient name different from the marketing name. It may be regulated as a cosmetic. Or the query itself may have failed, since the ingredient index is case sensitive and a product name search can return fewer records than an ingredient sweep. Absence from a search is not the same as absence from regulation, and it should not be read as either a red flag or a reassurance on its own. Is a mesotherapy cocktail a licensed product? A mixture assembled by a seller is not a licensed product, whatever its components were individually, and there is no register record to verify it against. Buying licensed components is a different transaction from buying someone's pre-mixed preparation, and only the former can be checked against a register record. What is the single most useful check? Lot and expiry agreement across the carton, the individual unit and the accompanying paperwork. It applies to every bucket regardless of register, it requires no database access, and disagreement between any two of the three is difficult to produce by accident. Disclaimer. This article is general educational information, current as of its publication date, and is not legal, medical or regulatory advice. Register contents change: the figures here were swept on a single date and records are granted and withdrawn continuously. Whether a specific product may be imported or used, and by whom, is determined by the relevant authorities and depends on approval status, classification and professional licensure in your own market. Confirming eligibility is the buyer's responsibility and, for prescription categories, runs through the appropriate licensed professional. Sources & references Ministry of Food and Drug Safety (MFDS), open data registers, swept on 10 August 2026. Drug product approval register queried on the active ingredient field for "Clostridium Botulinum Toxin Type A" (58 records; 57 live; class code toxins and toxoids on all 57; prescription-only supply classification on all 57; export naming on 24; oldest live record 13 July 1999) and for "Exosome" in three capitalisations (zero records in each). Medical device approval register queried on the product category for tissue repair biomaterial (609 records; 458 live). Supply classification, class code, licence route, holder and grant date fields were read from the licence records themselves. data.go.kr KSTATION, Editorial & Sourcing Policy (official-channel sourcing and traceable provenance). kstations.com/pages/editorial-policy The reason this guide leads with classification rather than with a checklist is that the classification step is the one buyers skip, and skipping it makes every subsequent check either irrelevant or misleading. For a category assembled around a technique rather than a product type, knowing which register holds your product is most of the work. What an accountable channel should be able to tell you is which bucket a given product is in, who holds its licence, and what its lot and provenance are. Whether that product is appropriate or permitted for your situation remains a matter for a qualified professional and your own authority.

A copper peptide booster label gives you two words and both of them are misleading if you read them the way the industry says them. The copper is not the active in the sense that copper supplements are copper. The peptide is three amino acids long, which is short enough that calling it a peptide puts it in the same bucket as molecules hundreds of times its size. And when you take the name to the Korean drug register to check what it is licensed as, the register returns nothing at all. That last part is not a failure of the search. We swept the register in full on 10 August 2026 and the active ingredient field returns zero records for copper tripeptide-1 and zero for tripeptide of any kind, while the same field on the same day returns 48 records for copper and 109 for dexpanthenol.1 The field works. The molecule is simply not in that register, and understanding why is most of what you need to read this category correctly. What GHK-Cu is, and what the two halves of the name do GHK-Cu is a copper complex of a three amino acid peptide, glycyl-L-histidyl-L-lysine, listed on cosmetic ingredient labels as copper tripeptide-1. The peptide half is the sequence glycine, histidine, lysine. The Cu half is a copper ion held by that sequence. The two are not mixed together in a vial as separate ingredients; the peptide binds the copper, and the bound form is the thing the literature discusses. The distinction matters more than it sounds. Copper on its own is a trace mineral with a well established nutritional role and a completely separate regulatory life, which is exactly what the Korean register shows when you ask it about copper. A peptide that binds copper is a different proposition: the sequence determines what the complex is, and the copper is carried rather than supplied. Reading GHK-Cu as "a way to get copper into skin" inverts the relationship the molecule is named for. The published characterisation is specific about this. The review most often cited in the category describes GHK as a human peptide with a high affinity for copper ions, and attributes its studied actions to the complex rather than to either component alone.2 That is a statement about what has been studied, not a statement about what any commercial product achieves, and the gap between those two things is where most copper peptide marketing lives. The practical read for anyone assessing a product is that the name copper peptide is a family name, not a specification. It tells you the class of molecule. It does not tell you which peptide, at what concentration, in what buffer, or whether the copper is actually complexed as intended in the finished solution. None of those are things a label is obliged to disclose, and in this category most do not. Is a copper peptide the same as a growth factor? No, and the difference is size and mechanism rather than category. A growth factor such as EGF is a protein of roughly fifty amino acids that binds a specific cell surface receptor. GHK-Cu is three amino acids carrying a metal ion. Both get filed under the loose commercial heading of regenerative actives, which is how they end up on the same shelf and in the same sentence, but they are not variants of one another. The confusion is worth clearing because it drives the wrong comparison at purchase. Buyers who have learned to interrogate growth factor products correctly ask which protein, at what concentration, from which expression system, because for a fifty amino acid protein those questions determine whether the material is what it claims. We walk through that in reading an EGF product. Applied to a tripeptide, the same questions are partly meaningless. There is no expression system for a three amino acid sequence in the sense there is for a protein; it is synthesised. What replaces those questions for a copper peptide is a different set. Is the copper complexed, and stable in the finished solution? What is the pH, given that copper complexation is pH dependent? Is the peptide the L form throughout? These are formulation questions rather than sourcing questions, which makes them harder to verify from outside and easier for a supplier to leave unaddressed. A specification sheet that names copper tripeptide-1 and stops has told you the family and nothing else. The other common conflation is with exosomes and with polynucleotides, both of which sit in the same commercial category and neither of which is chemically adjacent. The useful mental sort is by molecular class before anything else: a nucleotide polymer, a lipid vesicle carrying cargo, a protein, and a metal binding tripeptide are four different kinds of thing that a catalogue will list on one page. Our skin booster family by active lays that sort out. What the Korean register holds under copper, and what it holds under tripeptide Ask the Korean drug register for copper as an active ingredient and it returns 48 records, of which 39 are live. Ask it for copper tripeptide-1 and it returns nothing. Ask it for tripeptide in any form and it returns nothing. The zero is real rather than an artefact of the query, which is exactly what the 48 establishes: the field is populated and responsive on the same day, in the same sweep. Korean drug register, active ingredient field, swept in full on 10 August 2026 Queried active Total records Live What the live records are Copper tripeptide-1 0 0 Nothing Tripeptide (any) 0 0 Nothing Copper 48 39 Injectables filed as blood and body fluid agents, 7 of 7; non-injectables mostly dental and vitamin preparations Ectoin 0 0 Nothing Ectoine 0 0 Nothing Panthenol 2 0 Two single-use eye drops, both withdrawn Dexpanthenol 109 88 The same molecule under its pharmacopoeial name, across 57 licence holders Hyaluronic acid 4 4 Cross-linked sodium hyaluronate gels, which is a different product class from a booster Read the copper line carefully, because it is the one that tempts a wrong conclusion. The 39 live copper licences are not copper peptide products. Seven are injectables and all seven are filed under a register class the ministry names as other agents affecting blood and body fluids, which is the shape of a trace element supplementation product rather than an aesthetic one. The non-injectable remainder sits mostly in dental and vitamin classes. Copper is on that register as a nutrient, not as a peptide complex, and the oldest live entry dates to November 1990. There is a second detail in the copper set worth pausing on, because it shows how much context a register carries that a headline count does not. Of the 32 live non-injectable copper licences, 20 carry export wording in the licensed product name, and 15 of the 32 are filed under a dental and oral preparations class. That is not a picture of a domestic aesthetic ingredient. It is a picture of oral health and nutritional products, a substantial share of which were licensed for shipment elsewhere. A count of 39 live copper licences, quoted without that breakdown, would leave a reader with the impression that copper is a well established injectable active in Korea. Seven injectables in a blood and body fluid class, the oldest from 1990, is a different statement. So the accurate statement about a GHK-Cu booster is narrow and worth getting exactly right: the active is not licensed as a drug substance in Korea, and a product built on it is not a Korean drug register item. That is not a defect and it is not a red flag on its own. It is a category fact, and it is the same category fact that applies to a great many cosmetic ingredient actives. What it means practically is that the verification route most of this blog's readers have learned to use, which is to check the register and let it settle the argument, does not apply here. There is no entry to check. Panthenol or dexpanthenol: one molecule, two naming systems The most instructive line in that table is not the zero. It is the pair at the bottom. Search the register for panthenol and you get two records, both single-use eye drops, both withdrawn, so zero live. Search the same register on the same day for dexpanthenol and you get 109 records with 88 live, held across 42 non-injectable and 15 injectable licence holders, with the oldest live entry dating to 1986. These are not two different ingredients that happen to sound alike. Dexpanthenol is the D isomer, and it is the name the pharmacopoeial system uses; panthenol is the name the cosmetic ingredient system uses. One naming convention returns nothing usable and the other returns most of a category. The molecule did not change between the two searches. The vocabulary did. This is the single most transferable skill in reading any booster label against any register, and it generalises well beyond this ingredient. Cosmetic labels are written in one naming system and drug registers are written in another. Copper tripeptide-1 is a cosmetic ingredient name. Sodium hyaluronate and hyaluronic acid are used interchangeably in marketing and are not interchangeable in a register query. We hit the same wall from the opposite direction with tranexamic acid, where searching the product name field rather than the ingredient field quietly removed exactly the records that broke the pattern. The working rule that falls out of this: a zero result is a hypothesis, not a finding, until you have run a control on the same field. Ours here was copper at 48 and dexpanthenol at 109. Without those, the honest report on copper tripeptide-1 would have been that we could not tell whether the molecule is absent or the field is empty, and those are very different claims to publish. The supporting cast on a copper peptide booster label Copper peptide boosters are almost never single actives. The typical composition pairs the peptide with a hydrator, an osmolyte, and a barrier component, and each of those three has a different relationship to the register and a different weight in the formulation. Hyaluronic acid is the usual hydrating partner and the register read on it is counterintuitive. Four live records, all of them cross-linked sodium hyaluronate gels, which is the filler and joint injection side of the molecule rather than the booster side. The uncross-linked hyaluronic acid that appears in a booster is not sitting in that register at all, for the same structural reason a copper peptide is not. If that distinction is unfamiliar, our explainer on cross-linked versus uncross-linked HA is the one to read first, because it is the difference between two entirely different products sharing a molecule name. Ectoin returns zero on the register under both spellings we tried. It is an osmolyte, a small molecule that bacteria of high-salinity environments accumulate to stabilise proteins and membranes under osmotic stress, and in a cosmetic formulation it is included as a stabilising and protective component. It has no Korean drug licence because it is not a drug substance there, which by now should read as a category statement rather than a warning. Panthenol is the barrier component and the one with the naming trap described above. On a booster label it will be panthenol. In any pharmacopoeial context it is dexpanthenol, and under that name it is one of the better established small molecules in the register with 88 live licences. Notably, 20 of the 68 live non-injectable dexpanthenol licences are filed under a class the register names as other topical agents, and 14 more under an analgesic and anti-inflammatory class. Register class codes describe the target area rather than the dosage form, which is a trap we walked into on a previous sweep and is worth stating plainly: an oral tablet can legitimately carry a topical class code. Read as a group, the composition of a typical copper peptide booster is one signalling molecule and three supporting components whose jobs are hydration, stabilisation, and barrier support. That is a reasonable formulation logic. It is also, from a verification standpoint, four ingredients of which none can be checked against a Korean drug licence, which puts the entire weight of verification onto the manufacturer's documentation and the supply chain. Ready to use or reconstituted: what the supplied form tells you Copper peptide boosters are usually supplied as a liquid solution in a vial rather than as a lyophilised powder requiring reconstitution, and that choice is a genuine piece of information about the formulation rather than a convenience feature. A molecule is freeze dried when it is unstable in solution over a shelf life. That is why glutathione ships as a powder, which we set out in why glutathione ships freeze dried: it oxidises, so it is kept dry until the moment of use. A product supplied ready to use in a liquid has been formulated on the premise that its actives hold in that liquid for the stated shelf life, at the stated storage temperature. For a copper complex this is a more interesting claim than it looks. Copper complexation is pH sensitive, and free copper ions in solution are a different chemical proposition from complexed copper. A ready to use liquid presentation is therefore a statement that the formulation holds the complex stable in the buffer it ships in. It is not a statement anyone external can verify from a label, which is precisely why storage conditions and expiry become the parts of the label that carry real weight. Refrigerated storage between 2 and 8 degrees Celsius, protection from light, and a genuine unbroken cold chain are what makes such a claim credible in transit. The corollary is a sourcing point rather than a clinical one. A ready to use liquid that has spent an unknown period outside its stated temperature range has an unknown relationship to its own specification, and no amount of intact packaging tells you whether that happened. This is where a documented cold chain stops being a logistics detail and starts being part of the product. What the label can tell you and what it cannot is a longer subject, covered in reading an injectable's label. What to verify before buying a copper peptide booster Because the register route is closed for this active, verification shifts entirely onto documentation and provenance. The checks below are ordered by how much they actually discriminate between products, which is not the order most specification sheets present them in. Which peptide, named precisely. Copper tripeptide-1 is a specific INCI name. A sheet that says copper peptide or peptide complex without naming the entity has told you nothing checkable. Whether concentration is disclosed at all. Many suppliers in this category do not publish it. That is common, and worth knowing rather than assuming. An undisclosed concentration means comparative claims between two copper peptide products are unfootable in either direction, including favourable ones. Supplied form and storage. Liquid or lyophilised, the stated temperature range, and whether the shipping method actually holds it. These are verifiable and they interact. Who holds the licence, where the product is licensed at all. For an ingredient outside the drug register this means the cosmetic or equivalent registration in its market of origin, and the identity of the entity behind it. A brand name on a carton is not a manufacturer. What the supporting composition is, in full. A four ingredient disclosure is a stronger document than a one ingredient headline, because it is the one you can compare against what arrives. The check that does the most work in practice is the least technical one: compare the document you were sent before purchase against the carton and vial that arrive. Ingredient list, presentation, volume per vial, count per box, storage statement, and the entity named as responsible. Discrepancies at this stage are rarely dramatic, which is exactly why they get waved through. A composition list that gains or loses a supporting ingredient between the sheet and the carton, or a storage range that reads differently on the box than in the documentation, is a signal about how the supply chain is managed regardless of whether the product itself is what it claims. Two things are deliberately absent from that list. Neither the number of vials in a box nor the presence of a reconstitution step tells you anything about quality; they are packaging and formulation decisions. And no verification step available to a buyer establishes what a product does. That belongs to a clinical literature about the molecule, not to a supply document about a product. Sourcing GHK-Cu boosters, and what to verify Our position on this category follows from the register read rather than around it. Where an active has a Korean drug licence, we check it and let the register settle classification questions. Where an active sits outside that register, as copper tripeptide-1 does, we say so rather than implying a licence that does not exist, and the verification moves to manufacturer documentation, licence holder identity, and traceable provenance. Where a supplier sheet and a public record disagree, the public record wins. Our method is set out in the Editorial & Sourcing Policy.3 Applied to copper peptide products specifically, that means we do not present GHK-Cu as a licensed drug substance in Korea, we do not publish a concentration a supplier has not disclosed, and we do not attribute the published literature on the molecule to a particular commercial product. Those three restraints remove most of what the category's marketing consists of, which is the point of stating them. Peptide-led boosters sit in our skin boosters and ampoules and skin recovery and regeneration ranges alongside the polynucleotide and exosome lines, including CURION, which is built on copper tripeptide-1 and supplied ready to use, and SELASTIN EXO PLUS and CURENEX INTENSE GLOW & SHINE on different actives. For how the same register read plays out on an active that is licensed, see reading a PDRN skin booster. For how depth changes what any of these products is doing in tissue, see injection depth, intradermal versus subdermal. Frequently asked questions Frequently asked What is GHK-Cu?GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine, listed on cosmetic ingredient labels as copper tripeptide-1. It is three amino acids binding a copper ion, and the published literature discusses the bound complex rather than the peptide or the copper separately. It is not a growth factor and it is not a protein. Is a copper peptide the same as a growth factor?No. A growth factor such as EGF is a protein of roughly fifty amino acids that binds a specific cell surface receptor. GHK-Cu is a three amino acid peptide carrying a metal ion. They share a commercial shelf and a marketing category, not a molecular class, and the questions that verify one do not transfer cleanly to the other. Is GHK-Cu on the Korean drug register?No. A full sweep of the active ingredient field on 10 August 2026 returned zero records for copper tripeptide-1 and zero for tripeptide of any kind. The same field on the same day returned 48 records for copper and 109 for dexpanthenol, so the zero reflects the molecule's status rather than an empty field. Copper peptide products are cosmetic ingredient products in that market, which means verification runs through manufacturer documentation rather than a drug licence. What is copper tripeptide-1 usually paired with in a skin booster?Most commonly hyaluronic acid as a hydrating component, ectoin as a stabilising osmolyte, and panthenol as a barrier component. None of the four has a Korean drug licence in the form used in a booster, which is a category fact rather than a warning sign. Panthenol is the same molecule the pharmacopoeial system calls dexpanthenol, which has 88 live licences under that name. Does a ready to use booster need reconstitution?No. Ready to use means the product ships as a liquid solution with no dilution or reconstitution step. It also means the formulation is claimed to hold its actives stable in that liquid across the stated shelf life, which puts more weight on storage temperature, light protection, and an unbroken cold chain than a lyophilised product would. Disclaimer. This article is general educational information and is not medical advice. It describes what an ingredient is, how it is named, and how public registers do or do not record it; it makes no claim about what any product does, achieves, or is suitable for, and it is not a selection, preparation, or administration guide. Products referenced are intended for professional use by trained practitioners. Regulatory and customs requirements vary by country and change over time; confirm current requirements with the relevant authority. Sources & references Ministry of Food and Drug Safety (MFDS), drug product approval register, queried on the active ingredient field on 10 August 2026, all pages retrieved for each term: copper tripeptide-1 (0 records), tripeptide (0), copper (48; 39 live), ectoin and ectoine (0 each), panthenol (2; 0 live), dexpanthenol (109; 88 live), hyaluronic acid (4; 4 live). Register class, route, supply classification, holder counts and grant dates were read from the licence records themselves. data.go.kr Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. Cited here for the characterisation of GHK as a copper-binding human peptide, not for any claim about a commercial product. ncbi.nlm.nih.gov KSTATION, Editorial & Sourcing Policy (official-channel sourcing and traceable provenance). kstations.com/pages/editorial-policy

Some Korean licensed product names end with a word about export. It appears often enough that most people sourcing from Korea have seen it, and it is explained to them often enough that most have picked up a belief about what it means. Usually that belief is that export designation is a grade. We swept ten actives in full and counted every licence carrying that wording, and the register does not support that reading. It also does not support several of the other readings, including one we had drifted toward ourselves. The sweep covered 1,952 records on 10 August 2026, of which 1,578 are live.1 Two hundred and forty-six of the live licences carry export wording inside the licensed product name. That is one in six. This article is about what those 246 have in common, which turns out to be less than expected, and about four inferences that the distribution rules out. It is two markings, not one The first thing to fix is that export wording on a Korean licence is not a single thing. There are two distinct forms, and treating them as interchangeable produces a specific and consequential error. Export wording on live licences, ten actives, read 10 August 2026 Marking What the register is recording Live licences 수출용 The licence is designated for export 188 수출명 The name the product carries when exported 36 Both, on one licence Designated for export, and an export name recorded 22 Neither 1,332 The second marking is a naming convention. It records what a product is called abroad, and it attaches to licences that stand on their own terms. Read it as the first and you will describe a domestically licensed medicine as export only, which is wrong in a way that matters when the question is what a Korean licence covers. The clearest proof that they are different things is the third row. Twenty-two live licences carry both markings at once. If the two meant the same thing, no licence would ever need both, and the register would not have 22 of them. The oldest of the 22 shows what that looks like in practice. 대화데카비타민연질캡슐(수출용)(수출명:비타폴테연질캡슐), granted to 대화제약 in January 1988, carries the export designation in one parenthesis and the name it travels under in the next. Two separate pieces of information, recorded separately, inside a single product name. Fourteen of the 22 are ascorbic acid licences. Where this bites in practice Counting tools, including our own until we separated them, tend to collapse both markings into a single "export" tally. That inflates the apparent number of export-only products and, worse, misclassifies specific licences. The oldest live licence in our entire sweep is an example: a prescription capsule granted in July 1972 that carries an export name and is not export designated. It has been a domestically licensed Korean medicine for 54 years. A merged count would file it as export only. Not a quality tier The most common belief about export designation is that it marks a better product, made to a higher standard for foreign buyers. Nothing in the register supports this and nothing in the distribution looks like it. The 246 export-marked live licences split 151 over the counter and 95 prescription only. They span 54 years of grants, from that 1972 capsule to a hyaluronate injectable granted on 16 July 2026. They sit across the same class codes as everything else. There is no field on these licences that is absent from the others, no additional designation, and no grade recorded anywhere. Export-marked and unmarked licences are issued under the same regime, and the register treats them as the same kind of object. A product being export designated tells you about the licence category it sits in. It does not tell you it was made differently, and no licence in this sweep says otherwise. Not approval in your market The second belief is subtler and more consequential: that a Korean export designation is a form of clearance for the destination, or at least evidence that the product was intended to satisfy it. A Korean licence describes standing in Korea. That is the whole of what any entry on this register does, export-marked or not. Whether a product may be imported into a given market, by whom, and under what conditions is decided by the authority in that market applying its own framework, and it may reach a different answer about the same product. An export marking is a Korean administrative category recorded by a Korean regulator. It is not a foreign approval, and it is not evidence of one. Not a route story Here is where our own reading needed correcting. Looking at tranexamic acid alone, ten of 16 injectable licences carry export wording against two of 14 non-injectable ones, which is a strong enough split to suggest that export designation concentrates on injectables. It is a tempting story: injections travel, topicals stay home. It does not survive the wider sweep. Across all ten actives, 62 of 366 injectable licences carry export wording, which is 16.9 percent, against 184 of 1,212 non-injectable licences, which is 15.2 percent. Those two numbers are effectively the same. Tranexamic acid is real, but it is one molecule, and the pattern inside it is not a pattern across the register. Export designation is not decided by route. Not a signal that a licence will lapse The fourth correction is the one we would have got wrong if we had not checked, and it is worth showing the working. Writing about tranexamic acid we noted that three of that active's five exited licences were export-designated injectables. That is a striking concentration in a small set, and the natural next thought is that export licences are more disposable, kept alive only while a particular shipment relationship lasts. We ran it across all 1,952 records, live and exited, to find out. Exit rate by export marking, all records ever, ten actives Records Exited Exit rate Carries export wording 286 40 14.0% No export wording 1,666 334 20.0% The opposite of the hypothesis. Export-marked licences have left the register less often than unmarked ones, not more. The tranexamic acid observation was true about tranexamic acid and told us nothing about the register, which is what a five-record sample usually does. We are reporting the failed hypothesis rather than the finding we expected because the alternative is publishing a plausible pattern that a wider count refutes. This register rewards counting everything and punishes reasoning from the interesting cases, which are interesting precisely because they are unrepresentative. They also leave differently The rate is only half of it. The register records why each exited licence left, and the two groups do not leave the same way. Of the 40 export-marked records that have exited, 38 were withdrawn by the holder, one lapsed at the end of its validity period and one ended when the company closed. Withdrawal accounts for 95 percent. Among unmarked records the split runs the other way: of 334 exits, 181 lapsed at the end of a validity period and 138 were withdrawn, with the remaining 15 accounted for by company closures and administrative cancellations. Passive expiry is the single largest route out. Export-marked licences, in other words, are not quietly allowed to run down. They are given up on purpose. That is a different kind of fact from the exit rate and arguably a more informative one, because it says something about how holders treat these licences: as positions they decide to close rather than ones they forget to renew. What it does track Having ruled things out, here is what the distribution actually shows. It varies enormously by active. Export-marked share of live licences runs from zero to 40 percent across the ten. Export-marked share of live licences, by active Active Live licences Export-marked Share Tranexamic acid 30 12 40.0% Lidocaine 222 64 28.8% Heparin 52 11 21.2% Glutathione 73 14 19.2% Ascorbic acid 611 99 16.2% Hyaluronidase 32 4 12.5% Thioctic acid 158 18 11.4% Dexpanthenol 88 7 8.0% Sodium hyaluronate 266 17 6.4% Polydeoxyribonucleotide 46 0 0% One active has none at all. Polydeoxyribonucleotide returns zero export-marked licences out of 46, across injectables, creams and eye drops, and across every holder in the category. In a register where one live licence in six carries the marking, a clean zero across a whole active is worth noticing. We are not going to explain it, because the register does not, but anyone told that a Korean PDRN product is export grade should know that no such Korean licence exists. It concentrates in particular companies. The 246 export-marked live licences are held by 83 companies, and the distribution is uneven: one holder carries 15 of them, another 11, another nine, with several more in the seven-to-eight range. Look at what those holdings contain and the picture sharpens. 제일제약 holds 15 live licences across these ten actives and nine of them are export-marked, spread across six different actives: lidocaine, thioctic acid, hyaluronidase, ascorbic acid, dexpanthenol and heparin. 한국코러스 carries 15 export-marked licences out of 32, 동구바이오제약 11 out of 23. When a single holder marks half its portfolio for export across half a dozen unrelated molecules, the marking is describing the company rather than the product. And it is generational. Group the live licences by the decade they were granted in and the export-marked share falls almost monotonically. Export-marked share of live licences by grant era Granted Live licences Export-marked Share Before 1990 30 12 40.0% 1990 to 1999 75 39 52.0% 2000 to 2009 360 86 23.9% 2010 to 2019 709 77 10.9% 2020 onward 404 32 7.9% Over half of the surviving 1990s licences carry export wording, against under eight percent of those granted since 2020. One caveat belongs with that table: it counts licences that are still live, so it blends how often the marking was used in a given era with which licences from that era survived. It is not a clean measure of filing practice over time. But a drop from 52 percent to 7.9 percent is large enough that survivorship alone is unlikely to explain it, and the direction is consistent across four consecutive cohorts. What to do when you see it Read which marking it is. If the wording sits inside a parenthesis describing what the product is called abroad, the licence is a domestic one with an export name attached, and the product's Korean standing is whatever the rest of the record says. If the licence is designated for export, that is a category of Korean licence and nothing more. Then ignore it for the purposes you were probably about to use it for. It does not upgrade a product, it does not clear anything at the destination, and it does not predict whether the licence will still exist next year. The fields that do carry information are the ones we have been reading throughout this series: the ingredient string, the class code, the supply classification, the holder and the grant date. And if a supplier offers export designation as a selling point, that is worth noting for what it says about the supplier rather than the product. Licensing and manufacturer details are checked against the MFDS register before a product is listed, and where a supplier sheet and the register disagree, the register wins. We stock officially sourced products only, and the method is set out in our Editorial & Sourcing Policy.2 Our stocked range sits under vitamins and injectables and skin boosters and ampoules, including Detoxione Inj and CINDELLA Inj. For the field that does behave predictably, see what prescription only means when you import. For the register read on individual molecules, see what the register calls tranexamic acid, reading a thioctic acid injectable and reading a hyaluronidase vial. For the register's structure generally, see inside Korea's MFDS regulation. Frequently asked questions Frequently asked Is an export-designated Korean product higher grade?No. The register records no grade, and export-marked licences carry no field that unmarked ones lack. The 246 export-marked live licences in our sweep span both supply classifications, 54 years of grants and the same class codes as everything else. Export designation describes a licence category, not how a product was made. Does a Korean export licence mean approval in my country?No. A Korean licence describes standing in Korea only. Import eligibility and professional supply rules are decided by the authority in the destination market applying its own framework, and it can reach a different conclusion about the same product. An export marking is a Korean administrative category, not foreign clearance and not evidence of it. What is the difference between 수출용 and 수출명?The first indicates the licence is designated for export. The second records the name a product carries when exported, and attaches to licences that exist on their own terms. Among live licences we counted 188 with the first, 36 with the second, and 22 carrying both at once, which is the clearest evidence that they are not interchangeable. Are export licences more common on injectables?No, despite appearances in individual actives. Across ten actives, 16.9 percent of injectable licences carry export wording against 15.2 percent of non-injectable ones. Tranexamic acid alone shows a much sharper split, ten of 16 injectables against two of 14 non-injectables, but that pattern does not hold once the sample widens. Do export-designated licences get withdrawn more often?The opposite, in our data. Across all 1,952 records, 14.0 percent of export-marked licences have exited the register against 20.0 percent of unmarked ones. We tested this because a five-record observation in one active suggested otherwise, and it did not replicate. The manner of exit differs too: 38 of the 40 export-marked exits were withdrawn by the holder, whereas unmarked licences more often simply lapse at the end of a validity period. Is export wording still being used on new Korean licences?Less than it once was. Among live licences, 52 percent of those granted in the 1990s carry export wording against 7.9 percent of those granted since 2020, with the share falling across four consecutive cohorts. That count is of surviving licences, so it mixes usage with survival, but the direction is consistent and the size of the drop is hard to attribute to survivorship alone. New export-designated licences are still being granted: the most recent in our sweep dates to 16 July 2026. Why does one active have no export-marked licences at all?The register does not say, and we are not going to guess. What can be stated is the count: polydeoxyribonucleotide returns zero export-marked licences out of 46 live, across every format and every holder in that category, in a register where roughly one live licence in six carries the marking. Disclaimer. This article is general educational information. It is not legal, regulatory or medical advice, and it is not a guide to importing or exporting any product. It describes how export wording appears in Korean licensed product names and how those licences are distributed; it does not interpret Korean export law, and it makes no claim about what any active does or is suitable for. Products classified as prescription only are intended for professional use by trained practitioners. Import eligibility and customs requirements vary by country and change over time; confirm current requirements with the relevant authority in the destination market before acting. Sources & references Ministry of Food and Drug Safety (MFDS), drug product approval register, queried on the active ingredient field on 10 August 2026 for ten actives: Lidocaine, Tranexamic, Glutathione, Thioctic Acid, Hyaluronidase, Polydeoxyribonucleotide, Ascorbic Acid, Sodium Hyaluronate, Dexpanthenol and Heparin. All pages retrieved for each; 1,952 records in total, 1,578 live. Export wording was read from licensed product names and separated into the two forms; supply classification, class code, holder, grant date and withdrawal status were read from the licence records themselves. Figures are complete counts of that result set, not samples. data.go.kr KSTATION, Editorial & Sourcing Policy (official-channel sourcing and traceable provenance). kstations.com/pages/editorial-policy